Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer
Liquid biopsy may assist in the management of cancer patients, which can be particularly applicable in pancreatic ductal adenocarcinoma (PDAC). In this study, we investigated the utility of circulating cell-free DNA (cfDNA)-based markers as prognostic tools in metastatic PDAC. Plasma was obtained fr...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/7/1754 |
| _version_ | 1797563594448044032 |
|---|---|
| author | Marta Toledano-Fonseca M. Teresa Cano Elizabeth Inga Rosa Rodríguez-Alonso M. Auxiliadora Gómez-España Silvia Guil-Luna Rafael Mena-Osuna Juan R. de la Haba-Rodríguez Antonio Rodríguez-Ariza Enrique Aranda |
| author_facet | Marta Toledano-Fonseca M. Teresa Cano Elizabeth Inga Rosa Rodríguez-Alonso M. Auxiliadora Gómez-España Silvia Guil-Luna Rafael Mena-Osuna Juan R. de la Haba-Rodríguez Antonio Rodríguez-Ariza Enrique Aranda |
| author_sort | Marta Toledano-Fonseca |
| collection | DOAJ |
| description | Liquid biopsy may assist in the management of cancer patients, which can be particularly applicable in pancreatic ductal adenocarcinoma (PDAC). In this study, we investigated the utility of circulating cell-free DNA (cfDNA)-based markers as prognostic tools in metastatic PDAC. Plasma was obtained from 61 metastatic PDAC patients, and cfDNA levels and fragmentation were determined. BEAMing technique was used for quantitative determination of RAS mutation allele fraction (MAF) in cfDNA. We found that the prognosis was more accurately predicted by RAS mutation detection in plasma than in tissue. RAS mutation status in plasma was a strong independent prognostic factor for both overall survival (OS) and progression-free survival (PFS). Moreover, RAS MAF in cfDNA was also an independent risk factor for poor OS, and was strongly associated with primary tumours in the body/tail of the pancreas and liver metastases. Higher cfDNA levels and fragmentation were also associated with poorer OS and shorter PFS, body/tail tumors, and hepatic metastases, whereas cfDNA fragmentation positively correlated with RAS MAF. Remarkably, the combination of CA19-9 with MAF, cfDNA levels and fragmentation improved the prognostic stratification of patients. Furthermore, dynamics of RAS MAF better correlated with patients’ outcome than standard CA19-9 marker. In conclusion, our study supports the use of cfDNA-based liquid biopsy markers as clinical tools for the non-invasive prognosis and monitoring of metastatic PDAC patients. |
| first_indexed | 2024-03-10T18:44:44Z |
| format | Article |
| id | doaj.art-a3fd0be68b0b463e9679ea236e727039 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T18:44:44Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-a3fd0be68b0b463e9679ea236e7270392023-11-20T05:34:48ZengMDPI AGCancers2072-66942020-07-01127175410.3390/cancers12071754Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic CancerMarta Toledano-Fonseca0M. Teresa Cano1Elizabeth Inga2Rosa Rodríguez-Alonso3M. Auxiliadora Gómez-España4Silvia Guil-Luna5Rafael Mena-Osuna6Juan R. de la Haba-Rodríguez7Antonio Rodríguez-Ariza8Enrique Aranda9Maimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, SpainMedical Oncology Department, Reina Sofía University Hospital, E14004 Córdoba, SpainMedical Oncology Department, Reina Sofía University Hospital, E14004 Córdoba, SpainMedical Oncology Department, Reina Sofía University Hospital, E14004 Córdoba, SpainCancer Network Biomedical Research Center (CIBERONC), E28029 Madrid, SpainMaimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, SpainMaimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, SpainMaimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, SpainMaimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, SpainMaimónides Biomedical Research Institute of Córdoba (IMIBIC), E14004 Córdoba, SpainLiquid biopsy may assist in the management of cancer patients, which can be particularly applicable in pancreatic ductal adenocarcinoma (PDAC). In this study, we investigated the utility of circulating cell-free DNA (cfDNA)-based markers as prognostic tools in metastatic PDAC. Plasma was obtained from 61 metastatic PDAC patients, and cfDNA levels and fragmentation were determined. BEAMing technique was used for quantitative determination of RAS mutation allele fraction (MAF) in cfDNA. We found that the prognosis was more accurately predicted by RAS mutation detection in plasma than in tissue. RAS mutation status in plasma was a strong independent prognostic factor for both overall survival (OS) and progression-free survival (PFS). Moreover, RAS MAF in cfDNA was also an independent risk factor for poor OS, and was strongly associated with primary tumours in the body/tail of the pancreas and liver metastases. Higher cfDNA levels and fragmentation were also associated with poorer OS and shorter PFS, body/tail tumors, and hepatic metastases, whereas cfDNA fragmentation positively correlated with RAS MAF. Remarkably, the combination of CA19-9 with MAF, cfDNA levels and fragmentation improved the prognostic stratification of patients. Furthermore, dynamics of RAS MAF better correlated with patients’ outcome than standard CA19-9 marker. In conclusion, our study supports the use of cfDNA-based liquid biopsy markers as clinical tools for the non-invasive prognosis and monitoring of metastatic PDAC patients.https://www.mdpi.com/2072-6694/12/7/1754cell-free DNAliquid biopsyMAFpancreatic cancerRAS mutation |
| spellingShingle | Marta Toledano-Fonseca M. Teresa Cano Elizabeth Inga Rosa Rodríguez-Alonso M. Auxiliadora Gómez-España Silvia Guil-Luna Rafael Mena-Osuna Juan R. de la Haba-Rodríguez Antonio Rodríguez-Ariza Enrique Aranda Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer Cancers cell-free DNA liquid biopsy MAF pancreatic cancer RAS mutation |
| title | Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer |
| title_full | Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer |
| title_fullStr | Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer |
| title_full_unstemmed | Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer |
| title_short | Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer |
| title_sort | circulating cell free dna based liquid biopsy markers for the non invasive prognosis and monitoring of metastatic pancreatic cancer |
| topic | cell-free DNA liquid biopsy MAF pancreatic cancer RAS mutation |
| url | https://www.mdpi.com/2072-6694/12/7/1754 |
| work_keys_str_mv | AT martatoledanofonseca circulatingcellfreednabasedliquidbiopsymarkersforthenoninvasiveprognosisandmonitoringofmetastaticpancreaticcancer AT mteresacano circulatingcellfreednabasedliquidbiopsymarkersforthenoninvasiveprognosisandmonitoringofmetastaticpancreaticcancer AT elizabethinga circulatingcellfreednabasedliquidbiopsymarkersforthenoninvasiveprognosisandmonitoringofmetastaticpancreaticcancer AT rosarodriguezalonso circulatingcellfreednabasedliquidbiopsymarkersforthenoninvasiveprognosisandmonitoringofmetastaticpancreaticcancer AT mauxiliadoragomezespana circulatingcellfreednabasedliquidbiopsymarkersforthenoninvasiveprognosisandmonitoringofmetastaticpancreaticcancer AT silviaguilluna circulatingcellfreednabasedliquidbiopsymarkersforthenoninvasiveprognosisandmonitoringofmetastaticpancreaticcancer AT rafaelmenaosuna circulatingcellfreednabasedliquidbiopsymarkersforthenoninvasiveprognosisandmonitoringofmetastaticpancreaticcancer AT juanrdelahabarodriguez circulatingcellfreednabasedliquidbiopsymarkersforthenoninvasiveprognosisandmonitoringofmetastaticpancreaticcancer AT antoniorodriguezariza circulatingcellfreednabasedliquidbiopsymarkersforthenoninvasiveprognosisandmonitoringofmetastaticpancreaticcancer AT enriquearanda circulatingcellfreednabasedliquidbiopsymarkersforthenoninvasiveprognosisandmonitoringofmetastaticpancreaticcancer |